

August 1, 2018

Whom It May Concern

Company: KYORIN Holdings, Inc.  
Representative: Minoru Hogawa  
Representative Director, President  
(Security Code: 4569, TSE 1st Sec.)  
Contact: Shuji Miyaki  
Director, Corporate Communication  
President Office  
Telephone: (0)3-3525-4707

**KYORIN Pharmaceutical and FAES Farma Sign Agreement  
on Development and Distribution of Imidafenacin in Latin America**

**TOKYO, Japan (August 1, 2018)** – KYORIN Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan, President: Minoru Hogawa, “Kyorin Pharmaceutical”), a subsidiary of KYORIN Holdings, Inc., has executed a collaboration agreement with FAES FARMA, S.A. (Head office: Leioa, Spain, President: Mariano Ucar Angulo, “FAES”) for the exclusive development and distribution rights to Imidafenacin, a treatment for overactive bladder (OAB) that was discovered and developed by Kyorin Pharmaceutical, in Latin America (13 central and south countries including Brazil and Mexico).

Imidafenacin is a novel anticholinergic agent that acts as a selective antagonist on M3 and M1 muscarinic subtype receptors to improve the urgency of urination, pollakiuria and urge urinary incontinence associated with OAB. In Japan, Kyorin Pharmaceutical launched Imidafenacin under the brand name Uritos® 0.1mg tablets in June 2007. An additional dosage form of Orally Disintegrating (OD) tablet was launched in April 2011.

Under the philosophy to contribute to the health of people around the world, Kyorin Pharmaceutical continues to be actively engaged in the penetration of this agent in Japan and contributes to the QOL of patients suffering from symptoms of OAB. Further to such commitment, Kyorin Pharmaceutical aims to spread Imidafenacin in the market of Latin America with the partnership with FAES, and promotes its business globally.

It is expected that the impact of this transaction on consolidated financial forecasts for the fiscal year ending March 31, 2019 would be negligible.

###

### **About FAES FARMA S.A.**

Established in: 1933

President: Mariano Ucar Angulo

Revenue: EUR 274.6 million (2017)

Employees: 1,174

Overview: Founded in 1933, FAES Farma is a Spanish pharmaceutical company with a wide-ranging international projection, which develops, produces and commercializes pharmaceutical products and raw materials, exporting them to many countries.

The hallmarks of the company are an unrelenting commitment to excellence, constant striving for maximum pharmacological quality in all products with hard work that aims to offer highly effective solutions for patients.

FAES Farma is present in many countries, employing more than 1.100 people in its headquarters in Madrid, R&D center in Bilbao, the Vitoria laboratory in Lisbon and Diafarm laboratory, and its subsidiary companies and commercial offices abroad. It also owns the animal nutrition and healthcare companies Ingaso Farm, Tecnovit and Itf.

For more information, please visit [faesfarma.com](http://faesfarma.com).

### **About OAB**

Overactive Bladder (OAB) is a urological conditions characterized by difficulty in pooling urine in the bladder. Its predominant symptom is an urge to urinate, which is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence. One of the major problems of OAB is the fact that patients refrain from leaving the house due to anxiety about going to the bathroom, cannot get enough sleep at night, or face limitations in their daily activities, which could lead to significantly-reduced quality of life. Anticholinergic agents that show antagonistic effects, mainly on muscarinic receptors, are thought to be effective in treating OAB.